Semaglutide
Metabolic Dysfunction-Associated Steatohepatitis
Explore 128 assets in Metabolic Dysfunction-Associated Steatohepatitis →Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Cascade Pharmaceuticals, Inc
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07466017CT.gov A Study of CS060380 Tablets in Patients With MASH and Obesity | — | Recruiting | — | — | — |
NCT06492330CT.gov Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM | — | Completed | — | — | — |
NCT05877547CT.gov A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | — | Completed | — | — | — |
NCT05766709CT.gov A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations | — | Completed | — | — | — |
NCT05195944CT.gov Semaglutide vs Sitagliptin | — | Enrolling By Invitation | — | — | — |
NCT05016882CT.gov Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
NCT04971785CT.gov Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
NCT04944992CT.gov A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | — | Completed | — | — | — |
NCT04639414CT.gov Combined Active Treatment in Type 2 Diabetes with NASH | — | Active Not Recruiting | — | — | — |
NCT03987074CT.gov Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatohepatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Semaglutide (this asset) | Cascade Pharmaceuticals, Inc | Approved | BB · 71 |
| Resmetirom | City University of New York | P4 | BBB |
| Pentoxifylline | Al-Azhar University | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Firsocostat | Gilead Sciences | P2 | BBB |
| Rosuvastatin | Beni-Suef University | P4 | BBB |
| Montelukast | Tanta University | P4 | BBB |
| Alpha Tocopherol | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Ezetimibe | University of Palermo | P4 | BBB |
+42 more in the Metabolic Dysfunction-Associated Steatohepatitis cohort
Other indications for Semaglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 81 |
| Polycystic Ovary Syndrome | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/semaglutide-metabolic-dysfunction-associated-steatohepatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →